Healthcare delivered the most consistent sector performance in an otherwise fractured market Monday, with gains distributed across pharmaceuticals, biotechnology and managed care. Eli Lilly (LLY) led the large-capitalization names, rising 3.03% to $1,149.54 after opening at $1,142.20 and reaching $1,153.95, comfortably above its $1,130.50 session low.
AbbVie (ABBV) gained 2.08% to $262.47 and UnitedHealth Group (UNH) rose 1.63% to $385.27. Johnson & Johnson (JNJ) added 1.14% to $268.61, Gilead Sciences (GILD) climbed 1.41% to $145.75, Merck (MRK) advanced 0.88% to $145.19 and Amgen (AMGN) gained 0.82% to $380.45. Novo Nordisk (NVO) rose 0.87% to $43.45 and Pfizer (PFE) added 0.52% to $27.86.
Defensive Characteristics in Demand
The breadth of the advance — nine of nine major names higher, with no single-company catalyst driving the group — identifies the move as sector-level allocation rather than stock selection. Healthcare demand is largely non-discretionary, revenue is contractually or regulatorily insulated from the economic cycle, and balance sheets across large-capitalization pharmaceuticals carry substantial net cash.
Those attributes gained value against Monday's backdrop. Crude oil rose 2.80% to $102.85 per barrel, three-month SOFR futures repriced toward roughly 4.60% for September 2027 against approximately 3.98% for September 2026, and copper fell 2.63% to $6.376 per pound. Rising input costs paired with softening industrial demand is the configuration that most reliably drives allocators toward earnings streams disconnected from the cycle.